<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00029614</url>
  </required_header>
  <id_info>
    <org_study_id>NIAAABUK00301</org_study_id>
    <secondary_id>K24AA000301</secondary_id>
    <secondary_id>NIH Grant 5K24AA000301-05</secondary_id>
    <nct_id>NCT00029614</nct_id>
  </id_info>
  <brief_title>Atomoxetine to Treat Adolescents With Coexisting Alcohol and Other Substance Use Disorder and ADHD</brief_title>
  <official_title>Psychopharmacology of Adolescents With AUD and ADHD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness and safety of atomoxetine in the
      treatment of adolescents with coexisting alcohol or substance use disorders and Attention
      Deficit Hyperactivity Disorder (ADHD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>decrease in ADHD symptoms</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>decrease in the quantity and frequency of alcohol and other substance use</measure>
  </primary_outcome>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Substance Use Disorders</condition>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atomoxetine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adolescents, ages 13-18

          -  Meets criteria for alcohol and/or substance use disorder and attention deficit
             hyperactivity disorder.

        Exclusion Criteria:

          -  Adolescents who are pregnant.

          -  Have a history of seizure disorder, other neurological or medical disorder for which
             medication treatment may present a considerable risk.

          -  History of pervasive development disorder, schizophrenia or other psychotic disorders,
             organic mental disorders or eating disorders.

          -  Currently on other psychotropic medications from which discontinuation would present a
             significant risk.

          -  A current episode of major depressive disorder or a diagnosis of bipolar disorder.

          -  Diagnosis of dependence for any substance other than marijuana.

          -  Adolescents with a full-scale IQ below 80.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oscar G. Bukstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western Psychiatric Institute and Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Western Psychiatric Institute and Clinic</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2002</study_first_submitted>
  <study_first_submitted_qc>January 16, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2002</study_first_posted>
  <last_update_submitted>April 27, 2010</last_update_submitted>
  <last_update_submitted_qc>April 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2010</last_update_posted>
  <keyword>ADHD</keyword>
  <keyword>Substance Use</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atomoxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

